Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
American Gene Technologies to Present at 2020 Inborn Errors of Metabolism Drug Development Summit in Boston
March 10, 2020 09:34 ET
|
American Gene Technologies
ROCKVILLE, Md., March 10, 2020 (GLOBE NEWSWIRE) -- American Gene Technologies (AGT), a leading gene and cell therapy company in Rockville, Maryland, is pleased to announce its Chief Science Officer C....
Rubius Therapeutics Announces First Patient Dosed in Phase 1b Trial of RTX-134 for the Treatment of Patients with Phenylketonuria
January 30, 2020 08:00 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics Announces 2020 Objectives and Provides Operational Update at the 38th Annual J.P. Morgan Healthcare Conference
January 13, 2020 08:00 ET
|
Rubius Therapeutics
RTX-240 Investigational New Drug Application for Cancer on File with U.S. Food and Drug Administration Rubius Manufacturing Facility Operational Nine Months Ahead of Schedule and Ready to Supply...
Rubius Therapeutics Appoints Internationally Recognized Autoimmunity and Translational Immunology Leader Laurence Turka, M.D., as Chief Scientific Officer
January 08, 2020 08:00 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 02, 2020 16:05 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics Appoints Christina Coughlin, M.D., Ph.D., as Chief Medical Officer
December 23, 2019 08:00 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics Appoints Anne Prener, M.D., Ph.D., to its Board of Directors
December 18, 2019 08:05 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics Announces FDA Clearance of Investigational New Drug Application for First-Ever Red Cell Therapeutic, RTX-134, for Treatment of Phenylketonuria
March 11, 2019 08:00 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely...
Retrophin Recognizes Rare Disease Day® 2019 and Honors People Living with Rare Disease and Their Caregivers
February 28, 2019 08:00 ET
|
Retrophin, Inc.
SAN DIEGO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today joins the National Organization for Rare Disorders (NORD), the European Organisation for Rare Diseases (EURORDIS),...
Robin Li and Melissa Ma Donate RMB 660 Million to Peking University to Fund Tech Research and Innovation
April 28, 2018 15:38 ET
|
Baidu, Inc.
BEIJING, April 28, 2018 (GLOBE NEWSWIRE) -- Baidu, Inc. (NASDAQ:BIDU), the leading Chinese language Internet search provider, today announced that its Chairman and CEO Robin Li and his wife Melissa...